179 related articles for article (PubMed ID: 38439082)
1. MUC20 regulated by extrachromosomal circular DNA attenuates proteasome inhibitor resistance of multiple myeloma by modulating cuproptosis.
Wang X; Shi Y; Shi H; Liu X; Liao A; Liu Z; Orlowski RZ; Zhang R; Wang H
J Exp Clin Cancer Res; 2024 Mar; 43(1):68. PubMed ID: 38439082
[TBL] [Abstract][Full Text] [Related]
2. Mucin 20 modulates proteasome capacity through c-Met signalling to increase carfilzomib sensitivity in mantle cell lymphoma.
Wang X; Shirazi F; Yan W; Liu X; Wang H; Orlowski RZ; Wang H
J Cell Mol Med; 2021 Nov; 25(21):10164-10174. PubMed ID: 34651428
[TBL] [Abstract][Full Text] [Related]
3. Novel cell line models to study mechanisms and overcoming strategies of proteasome inhibitor resistance in multiple myeloma.
Brünnert D; Kraus M; Stühmer T; Kirner S; Heiden R; Goyal P; Driessen C; Bargou RC; Chatterjee M
Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1666-1676. PubMed ID: 30954557
[TBL] [Abstract][Full Text] [Related]
4. Modulating proteasome inhibitor tolerance in multiple myeloma: an alternative strategy to reverse inevitable resistance.
Ge M; Qiao Z; Kong Y; Liang H; Sun Y; Lu H; Xu Z; Liu H
Br J Cancer; 2021 Feb; 124(4):770-776. PubMed ID: 33250513
[TBL] [Abstract][Full Text] [Related]
5. MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma.
Qiang YW; Ye S; Chen Y; Buros AF; Edmonson R; van Rhee F; Barlogie B; Epstein J; Morgan GJ; Davies FE
Blood; 2016 Dec; 128(25):2919-2930. PubMed ID: 27793878
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the ʟ-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors.
Prelowska MK; Mehlich D; Ugurlu MT; Kedzierska H; Cwiek A; Kosnik A; Kaminska K; Marusiak AA; Nowis D
Cancer Lett; 2021 Jun; 507():13-25. PubMed ID: 33713737
[TBL] [Abstract][Full Text] [Related]
7. Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma.
Haertle L; Barrio S; Munawar U; Han S; Zhou X; Simicek M; Vogt C; Truger M; Fernandez RA; Steinhardt M; Weingart J; Snaurova R; Nerreter S; Teufel E; Garitano-Trojaola A; Da Viá M; Ruiz-Heredia Y; Rosenwald A; Bolli N; Hajek R; Raab P; Raab MS; Weinhold N; Haferlach C; Haaf T; Martinez-Lopez J; Einsele H; Rasche L; Kortüm KM
Clin Cancer Res; 2023 Jan; 29(1):279-288. PubMed ID: 36282272
[TBL] [Abstract][Full Text] [Related]
8. In vitro and ex vivo gene expression profiling reveals differential kinetic response of HSPs and UPR genes is associated with PI resistance in multiple myeloma.
Mitra AK; Kumar H; Ramakrishnan V; Chen L; Baughn L; Kumar S; Rajkumar SV; Van Ness BG
Blood Cancer J; 2020 Jul; 10(7):78. PubMed ID: 32724061
[TBL] [Abstract][Full Text] [Related]
9. A plastic SQSTM1/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells.
Milan E; Perini T; Resnati M; Orfanelli U; Oliva L; Raimondi A; Cascio P; Bachi A; Marcatti M; Ciceri F; Cenci S
Autophagy; 2015; 11(7):1161-78. PubMed ID: 26043024
[TBL] [Abstract][Full Text] [Related]
10. Silencing of MUC20 suppresses the malignant character of pancreatic ductal adenocarcinoma cells through inhibition of the HGF/MET pathway.
Chen ST; Kuo TC; Liao YY; Lin MC; Tien YW; Huang MC
Oncogene; 2018 Nov; 37(46):6041-6053. PubMed ID: 29993037
[TBL] [Abstract][Full Text] [Related]
11. ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF-κB in multiple myeloma.
Jiang J; Sun Y; Xu J; Xu T; Xu Z; Liu P
Cancer Med; 2020 Oct; 9(19):7244-7252. PubMed ID: 32780537
[TBL] [Abstract][Full Text] [Related]
12. AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma.
Gu C; Wang Y; Zhang L; Qiao L; Sun S; Shao M; Tang X; Ding P; Tang C; Cao Y; Zhou Y; Guo M; Wei R; Li N; Xiao Y; Duan J; Yang Y
J Exp Clin Cancer Res; 2022 Jan; 41(1):11. PubMed ID: 34991674
[TBL] [Abstract][Full Text] [Related]
13. MUC20 expression marks the receptive phase of the human endometrium.
Stepanjuk A; Koel M; Pook M; Saare M; Jääger K; Peters M; Krjutškov K; Ingerpuu S; Salumets A
Reprod Biomed Online; 2019 Nov; 39(5):725-736. PubMed ID: 31519421
[TBL] [Abstract][Full Text] [Related]
14. Encoding gene RAB3B exists in linear chromosomal and circular extrachromosomal DNA and contributes to cisplatin resistance of hypopharyngeal squamous cell carcinoma via inducing autophagy.
Lin C; Chen Y; Zhang F; Liu B; Xie C; Song Y
Cell Death Dis; 2022 Feb; 13(2):171. PubMed ID: 35194030
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic implications of mitochondrial stress-induced proteasome inhibitor resistance in multiple myeloma.
Sharma A; Nair R; Achreja A; Mittal A; Gupta P; Balakrishnan K; Edgar CL; Animasahun O; Dwivedi B; Barwick BG; Gupta VA; Matulis SM; Bhasin M; Lonial S; Nooka AK; Wiita AP; Boise LH; Nagrath D; Shanmugam M
Sci Adv; 2022 Sep; 8(39):eabq5575. PubMed ID: 36170375
[TBL] [Abstract][Full Text] [Related]
16. Exosome-Transmitted
Xu H; Han H; Song S; Yi N; Qian C; Qiu Y; Zhou W; Hong Y; Zhuang W; Li Z; Li B; Zhuang W
Clin Cancer Res; 2019 Mar; 25(6):1923-1935. PubMed ID: 30610101
[TBL] [Abstract][Full Text] [Related]
17. Activating
Shirazi F; Jones RJ; Singh RK; Zou J; Kuiatse I; Berkova Z; Wang H; Lee HC; Hong S; Dick L; Chattopadhyay N; Orlowski RZ
Proc Natl Acad Sci U S A; 2020 Aug; 117(33):20004-20014. PubMed ID: 32747568
[No Abstract] [Full Text] [Related]
18. Oxidatively modified low-density lipoproteins are potential mediators of proteasome inhibitor resistance in multiple myeloma.
Polusani SR; Cortez V; Esparza J; Nguyen HN; Fan H; Velagaleti GVN; Butler MJ; Kinney MC; Oyajobi BO; Habib SL; Asmis R; Medina EA
Int J Cancer; 2021 Jun; 148(12):3032-3040. PubMed ID: 33521927
[TBL] [Abstract][Full Text] [Related]
19. Extrachromosomal circular DNA in cancer: history, current knowledge, and methods.
Noer JB; Hørsdal OK; Xiang X; Luo Y; Regenberg B
Trends Genet; 2022 Jul; 38(7):766-781. PubMed ID: 35277298
[TBL] [Abstract][Full Text] [Related]
20. Increased serum extrachromosomal circular DNA SORBS1
Kong X; Wan SJ; Chen TB; Jiang L; Xing YJ; Bai YP; Hua Q; Yao XM; Zhao YL; Zhang HM; Wang DG; Su Q; Lv K
Cell Mol Biol Lett; 2024 Jan; 29(1):12. PubMed ID: 38212723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
